Oncohema Key

Pruritus David Croitoru Ehsan Azimi Maxwell B. Sauder The experience of pruritus among cancer patients is common, frequently leads to decreased quality of life, and may be related to multiple…

Radiation Therapy Beth McLellan ACUTE RADIATION DERMATITIS Acute radiation dermatitis (RD) occurs within 90 days after radiation therapy (RT). It is most common among patients with breast, head and neck,…

Programmed Cell Death 1 (PD-1)/Programmed Cell Death Ligand 1 (PD-L1) Inhibitors Jesse Hirner Brittany A. Klein Anna Kristine Dewan Programmed cell death 1 (PD-1) is a receptor found on T…

Thalidomide and Lenalidomide Pearl O. H. Ugwu-Dike Yevgeniy Semenov Thalidomide and lenalidomide are antiangiogenic, antineoplastic, immunomodulatory agents used in the management of a wide range of conditions. Thalidomide, historically used…

Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors Michael S. Chang Rebecca I. Hartman Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) functions as an immune checkpoint in negatively regulating T-cell function. T-cell activation requires…

CCR4 Inhibitors Cesar Antonio Virgen Cecelia Alejandra Larocca Mogamulizumab is the only FDA-approved C-C chemokine receptor type 4 (CCR4) inhibitor. It is approved for the treatment of relapsed or refractory…

Hormonal Therapies Jane J. Han Lauren M. Guggina Hormones, such as estrogen and androgens, are important in the initiation and proliferation of endocrine-sensitive cancers. Therefore, hormonal therapy is commonly used…

Proteasome Inhibitors Abdulhadi Jfri Victor Huang Ian W. Tattersall Proteasome inhibitors are a group of agents that inhibit the ubiquitin proteasome pathway, which regulates multiple cellular processes, including cell growth…

Fibroblast Growth Factor Receptor (FGFR) Inhibitors Catherine Pisano Christopher Iriarte Nicole R. LeBoeuf Fibroblast growth factors (FGFs) and their receptors (FGFRs) play an important role in normal cell biology, including…